Abstract
The effect of antiretroviral treatment on HIV-1 phenotype was studied in a group of 83 nucleoside-naive patients. These initially nonsyncytium-inducing HIV-1 positive patients were followed prospectively for their HIV-1 phenotype. Syncytium-inducing variants were detected by cocultivation of peripheral blood mononuclear cells with the MT-2 T-cell line. Overall, 16 of 83 (19%) patients underwent a shift to syncytium-inducing phenotype: 11 of 67 during zidovudine treatment, 3 of 10 during zidovudine plus alpha interferon treatment, and 2 of 6 under initial zidovudine plus didanosine therapy. The results of this study demonstrate that neither zidovudine therapy alone nor combined with interferon or didanosine prevents the acquisition of syncytium-inducing strains.
Similar content being viewed by others
References
Koot M, Keet IPM, Vos AHV, De Goede REY, Ross MTL, Coutinho RA, Miedema F, Schellekens PTA, Tersmette M: Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Annals of Internal Medicine 1993, 118: 681–688.
Buckheit RW, Germany-Decker J, Quails-Goodwin K, Bowdon BJ, Shannon WM: 3′-azido-3′-deoxythymidine-induced reduction in the ability of uninfected CD4-expressing cells to participate in syncytium formation. Proceedings of the National Academy of Sciences of the USA 1992, 89:8361–8365.
Bozzette SA, McCutchan JA, Spector SA, Wright B, Richman DD: A cross-sectional comparison of persons with syncytium- and non-syncytium-inducing human immunodeficiency virus. Journal of Infectious Diseases 1993, 168: 1374–1379.
Boucher CAB, Lange JMA, Miedema F, Weverling GJ, Koot M, Mulder JW, Goudsmidt J, Kellam P, Larder BA, Tersmette M: HIV-1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment. AIDS 1992, 6: 1259–1264.
Koot M, Schellekens PTA, Mulder JW, Lange JMA, Roos MTL, Coutinho RA, Tersmette M, Miedema F: Viral phenotype and T cell reactivity in human immunodeficiency virus type 1 -infected asymptomatic men treated with zidovudine. Journal of Infectious Diseases 1993, 168:733–736.
Leal M, Torres Y, Medrano FJ, Calderon EJ, Rey C, Lissen E: Does early zidovudine treatment prevent the emergence of syncytium-inducing human immunodeficiency virus? Journal of Infectious Diseases 1994, 170: 1041.
Delforge ML, Liesnard C, Debaisieux M, Tchetcheroff M, Farber CM, Van Vooren JP: In vivo inhibition of syncytium-inducing variants of HIV in patients treated with didanosine. AIDS 1995, 9: 89–101.
Schellekens PTA, Tersmette M, Roos MTL, Keet RP, de Wolf F, Coutinho RA, Miedema F: Biphasic rate of CD4+ cell count decline during progression to AIDS correlates with HIV-1 phenotype. AIDS 1992, 6: 665–669.
Richman DD, Bozzette SA: The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. Journal of Infectious Diseases 1994, 169:968–974.
Karlsson A, Parsmyr K, Sandström E, Fenyö EM, Albert J: MT-2 cell tropism as prognostic marker for disease progression in human immunodeficiency virus type 1 infection. Journal of Clinical Microbiology 1994, 32: 364–370.
Koot M, Vos AHV, Keet RPM, Goede REY, Dercksen MW, Terpstra FG, Coutinho RA, Miedema F, Tersmette M: HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay. AIDS 1992, 6:49–54.
Karlsson A, Parsmyr K, Aperia K, Sandström E, Fenyö EM, Albert J: MT-2 cell tropism of human immunodeficiency virus type 1 isolates as a marker for response to treatment and development of drug resistance. Journal of Infectious Diseases 1994, 170: 1367–1375.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Torres, Y., Leal, M., Rey, C. et al. Acquisition of syncytium-inducing HIV-1 strains during therapy with zidovudine alone or combined with alpha interferon or didanosine. Eur. J. Clin. Microbiol. Infect. Dis. 15, 324–327 (1996). https://doi.org/10.1007/BF01695665
Issue Date:
DOI: https://doi.org/10.1007/BF01695665